About Ben

Ben is recognised as one of Australia's leading intellectual property lawyers. He has extensive experience as an intellectual property specialist leading IP disputes and transactions in one of Australia’s pre-eminent IP teams. Ben is a patent and technology specialist with a degree in science (biochemistry) and leading expertise in IP licensing and commercialisation transactions, IP advice, litigation and dispute resolution. He also advises on pharmaceutical, biopharmaceutical and medical device regulatory matters, including on product registration and reimbursement issues, clinical trials, product launches and pharmaceutical supply and marketing issues.

Experience

• Samsung Bioepis

  Acting for Samsung Bioepis in successfully resisting an application to the Federal Court by Pfizer for preliminary discovery of documents relating to the manufacturing of Samsung Bioepis’s biosimilar etanercept product.

• Sun Pharma

  Acting for Sun Pharma in proceedings brought in the Federal Court by Mylan Health for alleged infringement of three patents for formulations and second medical uses of fenofibrate, together with cross claims for revocation of the patents.

• St Vincent’s Hospital Sydney

  Acting for St Vincent’s Hospital Sydney in negotiating patent license agreements with AVEO Pharmaceuticals, Inc. and Novo Nordisk granting exclusive worldwide rights to commercialise MIC-1, analogues and antibodies for a range of indications.

• Medical device company

  Acting for a leading medical device company in drafting and negotiating a number of transactions with suppliers, manufacturers and collaborators for the development of components for medical devices, including resolution of product supply, joint development, technology access and IP license and commercialisation issues.

• Actavis

  Acting for Actavis in proceedings brought in the Federal Court by Orion Corporation and Novartis Pharmaceuticals and on appeal to the Full Court for alleged infringement of a patent for triple formulations of levodopa, carbidopa and entacapone, and a cross claim for revocation of the patent.